ABSTRACT
BACKGROUND & AIMS: Lipodystrophies are hypoleptinemic conditions characterized by fat loss, severe insulin resistance, hypertriglyceridemia, and ectopic fat accumulation. Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are also features of this condition. We studied the spectrum of liver disease in lipodystrophy and the effects of leptin replacement. METHODS: This was an open-label, prospective study of leptin therapy in patients with inherited and acquired lipodystrophy at the National Institutes of Health. Liver biopsies were performed at baseline (N=50) and after leptin replacement (N=27). NASH activity was assessed using the NASH Clinical Research Network (CRN) scoring system. Fasting blood glucose, triglyceride, hemoglobin A1c and liver enzymes were measured at baseline and at the time of the final liver biopsy. RESULTS: In leptin-treated patients, 86% met criteria for NASH at baseline, while only 33% had NASH after leptin replacement for 25.8 ± 3.7 months (mean ± SE, p=0.0003). There were significant improvements in steatosis grade (reduction of mean score from 1.8 to 0.9) and ballooning injury scores (from 1.2 to 0.4), with a 44.2% reduction in mean NAFLD activity score (p<0.0001). Patients who already had fibrosis remained stable on leptin replacement. We observed significant improvement in metabolic profile, ALT and AST. In addition to NASH, four patients with acquired generalized lipodystrophy (AGL) had autoimmune hepatitis. CONCLUSIONS: The fundamental liver disease of lipodystrophy is NASH, although autoimmune hepatitis was observed in some patients with AGL. Leptin appears to be a highly effective therapy for NASH in hypoleptinemic lipodystrophic patients.
Subject(s)
Fatty Liver/drug therapy , Fatty Liver/etiology , Leptin/analogs & derivatives , Lipodystrophy/complications , Lipodystrophy/drug therapy , Adolescent , Adult , Aged , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Child , Cohort Studies , Fatty Liver/pathology , Female , Hepatitis, Autoimmune/drug therapy , Hepatitis, Autoimmune/etiology , Hepatitis, Autoimmune/pathology , Humans , Leptin/therapeutic use , Lipodystrophy/pathology , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Metabolome/drug effects , Middle Aged , Non-alcoholic Fatty Liver Disease , Prospective Studies , Recombinant Proteins/therapeutic use , Young AdultABSTRACT
Sphingosine 1-phosphate (S1P) is a bioactive lipid generated during vascular injury that regulates cell growth, differentiation, survival, and motility via endothelial differentiation gene (EDG) family G protein-coupled receptors. Although several G protein-coupled receptor ligands transactivate receptor tyrosine kinases, such as the epidermal growth factor receptor (EGFR), S1P-stimulated receptor tyrosine kinase transactivation has not been well studied. We show that platelet-derived growth factor beta receptor (PDGFbetaR) and EGFR are tyrosine phosphorylated in response to S1P in rat aortic vascular smooth muscle cells (VSMCs). S1P-stimulated transactivation of PDGFbetaR and EGFR was mediated via Gi-coupled EDG receptors. S1P-stimulated transactivation of EGFR and PDGFbetaR was dependent on Src, reactive oxygen species, and cholesterol-rich membranes. A phosphoinositide 3-kinase-Akt pathway was activated by S1P and blocked by AG1296 and AG1478. Activation of extracellular signal-regulated kinase (ERK) 1 and ERK2 pathway by S1P was blocked only by AG1478. In Chinese hamster ovary cells that expressed exogenous EDG-1, activation of Akt and ERK1/2 in response to S1P was observed and was enhanced by coexpression of PDGFbetaR or EGFR. S1P-mediated VSMC proliferation was shown to be secondary to transactivation, because it was suppressed by AG1296 and AG1478. These data establish S1P as an important stimulus for EGFR and PDGFbetaR activation in VSMCs that may have important implications for the vessel response to injury.
Subject(s)
ErbB Receptors/biosynthesis , Lysophospholipids/pharmacology , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/drug effects , Receptor, Platelet-Derived Growth Factor beta/biosynthesis , Sphingosine/pharmacology , Transcriptional Activation/drug effects , Animals , Aorta , CHO Cells , Cricetinae , Cricetulus , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , ErbB Receptors/genetics , GTP-Binding Protein alpha Subunits, Gi-Go/physiology , MAP Kinase Signaling System/drug effects , Membrane Lipids/physiology , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolism , Phosphatidylinositol 3-Kinases/physiology , Phosphorylation/drug effects , Protein Processing, Post-Translational/drug effects , Protein Serine-Threonine Kinases/physiology , Proto-Oncogene Proteins/physiology , Proto-Oncogene Proteins c-akt , Quinazolines , Rats , Rats, Sprague-Dawley , Receptor, Platelet-Derived Growth Factor beta/genetics , Sphingosine/analogs & derivatives , Superoxides/metabolism , Tyrphostins/pharmacologyABSTRACT
Fluid shear stress generated by blood flowing over the endothelium is a major determinant of arterial tone, vascular remodeling, and atherogenesis. Nitric oxide (NO) produced by endothelial NO synthase (eNOS) plays an essential role in regulation of vascular function and structure by blood flow, but the molecular mechanisms that transduce mechanical force to eNOS activation are not well understood. In this study, we found that laminar flow (shear stress=12 dyne/cm2) rapidly activates vascular endothelial growth factor receptor 2 (VEGFR2) in a ligand-independent manner and leads to eNOS activation in cultured endothelial cells. Flow-stimulated VEGFR2 recruits phosphoinositide 3-kinase and mediates activation of Akt and eNOS. Inhibiting VEGFR2 kinase with selective inhibitors blocks flow-induced activation of Akt and eNOS and production of NO. Decreasing VEGFR2 expression with antisense VEGFR2 oligonucleotides significantly attenuates activation of Akt and eNOS. Furthermore, Src kinases are involved in flow-stimulated VEGFR2 because inhibiting Src kinases by PP2, a selective inhibitor for Src kinases, abolishes flow-induced VEGFR2 tyrosine phosphorylation and downstream signaling. Finally, we show that inhibiting VEGFR2 kinase significantly reduces flow-mediated NO-dependent arteriolar dilation in vivo. These data identify VEGFR2 as a key mechanotransducer that activates eNOS in response to blood flow.
Subject(s)
Endothelium, Vascular/metabolism , Nitric Oxide Synthase/metabolism , Protein Serine-Threonine Kinases , Vascular Endothelial Growth Factor Receptor-2/metabolism , Animals , Antibodies, Monoclonal/pharmacology , Benzoquinones , Blood Vessels/drug effects , Blood Vessels/physiology , Cell Line , Cheek/blood supply , Cricetinae , Endothelium, Vascular/cytology , Endothelium, Vascular/enzymology , Enzyme Activation , Enzyme Inhibitors/pharmacology , Genistein/pharmacology , Integrin alphaVbeta3/immunology , Lactams, Macrocyclic , Ligands , Nitric Oxide/biosynthesis , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation/drug effects , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Quinones/pharmacology , Rifabutin/analogs & derivatives , Signal Transduction/drug effects , Stress, Mechanical , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , Vascular Endothelial Growth Factor Receptor-2/genetics , Vasodilation/drug effects , src-Family Kinases/metabolismABSTRACT
OBJECTIVE: Cyclophilin A (CyPA) is an abundant intracellular protein that is considered to be the main target of the immunosuppressive drug cyclosporine A. We and others showed that CyPA is secreted from smooth muscle cells and macrophages in response to oxidative stress and lipopolysaccharide, suggesting a role for CyPA in inflammation. We therefore studied the proinflammatory effects of CyPA on vascular endothelium. METHODS AND RESULTS: Because atherosclerosis is an inflammatory disease, we studied expression of CyPA in atherosclerotic plaques from the ApoE-/- mouse. Using immunohistochemistry, we showed that CyPA was highly expressed in these plaques. Because endothelial cells (EC) are important mediators of inflammation, we next studied the ability of CyPA to activate EC. Human recombinant CyPA activated mitogen-activated protein kinases, including ERK1/2, JNK, and p38 in cultured human umbilical vein EC. CyPA also stimulated IkappaB-alpha phosphorylation and NF-kappaB activation, and induced expression of adhesion molecules including E-selectin and vascular cell adhesion molecule-1. Furthermore, the combination of CyPA and cycloheximide induced EC apoptosis similar to the proapoptotic effect of tumor necrosis factor-alpha. CONCLUSIONS: Our data indicate that CyPA has proinflammatory effects on EC and may play an important role in the pathogenesis of inflammatory diseases, such as atherosclerosis.
Subject(s)
Cyclophilin A/physiology , Inflammation/metabolism , Animals , Apolipoproteins E/deficiency , Apolipoproteins E/genetics , Apoptosis/drug effects , Arteriosclerosis/etiology , Arteriosclerosis/metabolism , Cell Adhesion Molecules/biosynthesis , Cell Adhesion Molecules/genetics , Cells, Cultured/drug effects , Cells, Cultured/metabolism , Cyclophilin A/biosynthesis , Cyclophilin A/pharmacology , Cyclophosphamide/pharmacology , Endothelial Cells/drug effects , Endothelial Cells/metabolism , Endothelium, Vascular/cytology , Gene Expression Regulation/drug effects , Humans , I-kappa B Proteins/metabolism , MAP Kinase Signaling System/drug effects , Mice , Mice, Knockout , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Oxidative Stress , Recombinant Fusion Proteins/pharmacology , Recombinant Fusion Proteins/physiologySubject(s)
Angiofibroma/diagnosis , Multiple Endocrine Neoplasia Type 1/diagnosis , Skin Neoplasms/diagnosis , Adrenalectomy/methods , Angiofibroma/complications , Biopsy, Needle , Collagen Diseases/complications , Collagen Diseases/diagnosis , Fatigue/complications , Fatigue/diagnosis , Follow-Up Studies , Humans , Immunohistochemistry , Male , Middle Aged , Multiple Endocrine Neoplasia Type 1/surgery , Nephrolithiasis/complications , Nephrolithiasis/diagnosis , Pancreatectomy , Recurrence , Risk Assessment , Severity of Illness Index , Skin Neoplasms/complications , Splenectomy/methods , Vision Disorders/complications , Vision Disorders/diagnosisABSTRACT
CONTEXT: Leptin alters bone and mineral metabolism in rodents, but this has not been verified in humans. PATIENTS with congenital generalized lipodystrophy (CGL) have low leptin due to deficient adipose mass and serve as models of leptin deficiency and replacement. OBJECTIVE: To study the effects of recombinant human methionyl leptin (metreleptin) on bone mineral content (BMC) and mineral metabolism. DESIGN AND SETTING: An open-label nonrandomized study at the National Institutes of Health. PATIENTS: Thirty-one patients with CGL (ages 4.3 to 46.7 y). INTERVENTION: Metreleptin (0.06 to 0.24 mg/kg/d) for 6 months to 11 years. OUTCOME MEASURES: BMC was assessed by dual-energy x-ray absorptiometry. SD scores (SDS) for BMC were calculated based on height, race, sex, and age using population normative data. Calcium, phosphorus, PTH, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D were measured at baseline and follow-up. RESULTS: At baseline, patients demonstrated significantly increased total body less head BMC (mean SDS, 1.8 ± 0.7), height (mean SDS, 1.3 ± 1.3), and lean mass index, defined as lean body mass per height squared (mean SDS, 1.5 ± 0.83), vs population normative data. No change in total body less head BMC was observed after metreleptin. Lean mass index decreased with metreleptin. Serum calcium decreased with metreleptin, but remained within normal limits. No changes were seen in phosphorus, PTH, or vitamin D. CONCLUSIONS: In contrast to rodent models, CGL patients have increased BMC in the leptin-deficient state, which does not change with leptin replacement. The high BMC in these patients is partially explained by high lean mass and tall stature.
Subject(s)
Bone Density/drug effects , Hormone Replacement Therapy , Leptin/analogs & derivatives , Lipodystrophy, Congenital Generalized/drug therapy , Absorptiometry, Photon , Adolescent , Adult , Body Composition/drug effects , Bone Development/drug effects , Child , Child, Preschool , Female , Humans , Leptin/pharmacology , Leptin/therapeutic use , Lipodystrophy, Congenital Generalized/metabolism , Lipodystrophy, Congenital Generalized/physiopathology , Male , Young AdultABSTRACT
CONTEXT: The lipodystrophies (LD) are characterized by metabolic abnormalities (insulin resistance, hypertriglyceridemia, and diabetes) and a polycystic ovarian syndrome (PCOS) phenotype. Therapeutic administration of leptin improves insulin sensitivity and the metabolic features. OBJECTIVE: The objective of the study was to investigate whether the PCOS features are corrected by increasing insulin sensitivity as a function of leptin treatment. DESIGN: This was a prospective, open-label trial using leptin replacement in various forms of lipodystrophy. SETTING: The study was performed at the Clinical Center at the National Institutes of Health. PATIENTS OR OTHER PARTICIPANTS: Twenty-three female patients with LD were enrolled in a leptin replacement trial from 2000 to the present. Different parameters were assessed at baseline and after 1 yr of therapy. INTERVENTION(S): Patients were treated with leptin for at least 1 yr. MAIN OUTCOME MEASURE(S): We evaluated free testosterone, SHBG, and IGF-I at baseline and after 1 yr of leptin. RESULTS: Testosterone levels decreased from 3.05 ±0.6 ng/ml at baseline to 1.7 ±0.3 ng/ml (P = 0.02). SHBG increased from 14.5 ±2 to 25 ±3.5 nmol/liter after 1 yr of leptin therapy. There were no significant changes in the levels of gonadotropins and ovarian size as a result of leptin replacement therapy. IGF-I increased significantly after leptin therapy from 150 ±14 to 195 ±17. There was a significant decrease in triglycerides and glycosylated hemoglobin in the context of reduced insulin requirements. CONCLUSIONS: In the present study, we show that LD may be a model for the common forms of PCOS and that the endocrine features are corrected by leptin therapy, which reduces insulin resistance.
Subject(s)
Hyperandrogenism/etiology , Insulin Resistance/physiology , Lipodystrophy/complications , Polycystic Ovary Syndrome/complications , Adolescent , Adult , Child , Female , Follow-Up Studies , Hormone Replacement Therapy , Humans , Hyperandrogenism/drug therapy , Hyperandrogenism/metabolism , Leptin/therapeutic use , Lipodystrophy/drug therapy , Lipodystrophy/metabolism , Polycystic Ovary Syndrome/drug therapy , Polycystic Ovary Syndrome/metabolism , Time Factors , Young AdultABSTRACT
Lipodystrophy is a rare disorder characterized by loss of adipose tissue and low leptin levels. This condition is characterized by severe dyslipidemia, insulin resistance, diabetes mellitus, and steatohepatitis. Another phenotypic feature that occurs with considerable frequency in generalized lipodystrophy is cardiomyopathy. We report here the cardiac findings in a cohort of patients with generalized congenital and acquired lipodystrophy, and present a literature review of the cardiac findings in patients with generalized lipodystrophy. We studied 44 patients with generalized congenital and acquired lipodystrophy, most of them enrolled in a clinical trial of leptin therapy. Patients underwent electrocardiograms and transthoracic echocardiograms to evaluate their cardiac status. We followed these patients for an extended time period, some of them up to 8 years. Evaluation of our cohort of patients with generalized lipodystrophy shows that cardiomyopathy is a frequent finding in this population. Most of our patients had hypertrophic cardiomyopathy, and only a small number had features of dilated cardiomyopathy. Hypertrophic cardiomyopathy was more frequent in patients with seipin mutation, a finding consistent with the literature. The underlying mechanism for cardiomyopathy in lipodystrophy is not clear. Extreme insulin resistance and the possibility of a "lipotoxic cardiomyopathy" should be entertained as possible explanations.
Subject(s)
Cardiomyopathies/etiology , Lipodystrophy/complications , Adolescent , Adult , Aged , Child , Cohort Studies , Echocardiography , Electrocardiography , Female , Genotype , Humans , Lipodystrophy, Congenital Generalized/complications , Lipodystrophy, Congenital Generalized/genetics , Male , Middle Aged , Young AdultABSTRACT
Fluid shear stress generated by blood flowing over the endothelium is a major determinant of arterial tone, vascular remodeling, and atherogenesis. Nitric oxide (NO) produced by endothelial NO synthase (eNOS) plays an essential role in regulation of vascular function and structure by blood flow. Although cyclosporin A (CsA), an inhibitory ligand of cyclophilin A, is a widely used immunosuppressive drug, it causes arterial hypertension in part by impairing eNOS-dependent vasodilation. Here we show that CsA inhibits fluid shear stress-mediated eNOS activation in endothelial cells via decreasing cholesterol content in caveolae. Exposure of cultured bovine aortic endothelial cells to 1 mum CsA for 1 h significantly inhibited NO production and eNOS phosphorylation at Ser-1179 induced by flow (shear stress=dynes/cm2). The effect of CsA was not related to inhibition of two known eNOS kinases, protein kinase B (Akt) and protein kinase A, because CsA did not affect Akt or protein kinase A activation. In rabbit aorta perfused ex vivo, CsA also significantly inhibited flow-induced eNOS phosphorylation at Ser-1179 but had no effect on Akt measured by phosphorylation at Ser-473. However, CsA treatment decreased cholesterol content in caveolae and displaced eNOS from caveolae, which may be caused by CsA disrupting the association of caveolin-1 and cyclophilin A. The magnitude of the cholesterol depleting effect was similar to that of beta-cyclodextrin, a cholesterol-binding molecule, and beta-cyclodextrin had a similar inhibitory effect on flow-mediated eNOS activation. Treating bovine aortic endothelial cells for 24 h with 30 mug/ml cholesterol blocked the CsA effect and restored eNOS phosphorylation in response to flow. These data suggest that decreasing cholesterol content in caveolae by CsA is a potentially important pathogenic mechanism for CsA-induced endothelial dysfunction and hypertension.